Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies

被引：6

作者：

Fauziya ^{[1
]}

Gupta, Akash ^{[1
]}

Nadaf, Arif ^{[1
]}

Ahmad, Shadaan ^{[1
]}

Hasan, Nazeer ^{[1
]}

Imran, Mohammad ^{[1
]}

Sahebkar, Amirhossein ^{[2
]}

Jain, Gaurav Kumar ^{[3
]}

Kesharwani, Prashant J. ^{[1
,4
]}

Ahmad, Farhan ^{[1
]}

机构：

[1] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India

[2] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Iran

[3] Delhi Pharmaceut Sci & Res Univ DPSRU, Dept Pharmaceut, New Delhi, India

[4] Saveetha Inst Med & Tech Sci, Saveetha Dent Coll, Ctr Transdisciplinary Res, Dept Pharmacol, Chennai, India

来源：

MEDICAL ONCOLOGY | 2023年 / 40卷 / 06期

关键词：

Cancer; Dasatinib; Tyrosine kinase inhibitor; Solubility; Bioavailability; Side effects; Formulations; CHRONIC MYELOID-LEUKEMIA; NANOSTRUCTURED LIPID CARRIERS; DRUG-INTERACTIONS; CHRONIC PHASE; GROWTH; SRC; PHARMACOKINETICS; COMBINATION; RESISTANCE; BMS-354825;

D O I：

10.1007/s12032-023-02018-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dasatinib is the 2nd generation TKI (Tyrosine Kinase Inhibitor) having the potential to treat numerous forms of leukemic and cancer patients and it is 300 times more potent than imatinib. Cancer is the major cause of death globally and need to enumerate novel strategies to coping with it. Various novel therapeutics introduced into the market for ease in treating various forms of cancer. We reviewed and evaluated all the related aspects of dasatinib, which can enhance the knowledge about dasatinib therapeutics methodology, pharmacodynamic and pharmacokinetics, side effects, advantages, disadvantages, various kinds of interactions and its novel formulations as well.

引用

页数：23

共 50 条

[1] Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies
Akash Fauziya
Arif Gupta
Shadaan Nadaf
Nazeer Ahmad
Mohammad Hasan
Amirhossein Imran
Gaurav Kumar Sahebkar
Prashant Jain
Farhan J. Kesharwani
Medical Oncology, 40
[2] Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging
Rodriguez-Agustin, Andrea
Casanova, Victor
Grau-Exposito, Judith
Sanchez-Palomino, Sonsoles
Alcami, Jose
Climent, Nuria
PHARMACEUTICS, 2023, 15 (03)
[3] A CASE OF TYROSINE KINASE INHIBITOR (DASATINIB)-INDUCED ANGIOEDEMA
Peterson, J.
Toro, J.
Welch, N.
Lalmuanpuii, J.
Tarbox, J.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S110 - S110
[4] Inhibition of PVR with a Tyrosine Kinase Inhibitor, Dasatinib, in the Swine
Umazume, Kazuhiko
Liu, LanHsin
Scott, Patrick A.
de Castro, Juan P. Fernandez
McDonald, Kevin
Kaplan, Henry J.
Tamiya, Shigeo
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (02) : 1150 - 1159
[5] Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Tan, Fiona H.
Putoczki, Tracy L.
Stylli, Stanley S.
Luwor, Rodney B.
ONCOTARGETS AND THERAPY, 2019, 12 : 635 - 645
[6] Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer
Zamecnikova, Adriana
EXPERT OPINION ON DRUG DISCOVERY, 2014, 9 (01) : 77 - 92
[7] The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
Vandyke, K.
Fitter, S.
Zannettino, A. C. W.
BLOOD CANCER JOURNAL, 2011, 1 : e2 - e2
[8] The Tyrosine Kinase Inhibitor Dasatinib Decreases Osteoclast Formation and Activity in vitro
Vandyke, K.
Dewar, A. L.
Davis, A. N.
Fiuer, S.
Hughes, T. P.
To, L. B.
Zannettino, A. C. W.
JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S260 - S261
[9] The tyrosine kinase inhibitor dasatinib inhibits the functions of human phagocytes in vitro
Futosi, K.
Nemeth, T.
Mocsai, A.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2011, 41 : 48 - 48
[10] The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
K Vandyke
S Fitter
A C W Zannettino
Blood Cancer Journal, 2011, 1 : e2 - e2

← 1 2 3 4 5 →